Edesa Biotech reports Q2 net loss of $1.6M; advances vitiligo drug EB06 to Phase 2

Edesa Biotech, Inc.

Net loss of $1.6M ($0.30/share) vs $1.9M ($0.58) in prior-year Q2; operating expenses fell to $1.6M.
Completed $15M equity financing from institutional investors; cash and equivalents total $13.9M.
EB06 Phase 2 IND submission to FDA expected H2 2025; topline results 12-18 months after clearance.
EB05 ARDS study fully funded by government; R&D spend shifted from EB05 to EB06 program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.